. . "14110" . "Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year results"@en . "Pegaptanib (Macugen) je v \u010Cesk\u00E9 republice dostupn\u00FD pro l\u00E9\u010Dbu neovaskul\u00E1rn\u00ED formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace od dubna 2007. Pegaptanib je de facto prvn\u00EDm z\u00E1stupcem l\u00E1tek p\u016Fsob\u00EDc\u00EDch proti vaskul\u00E1rn\u00EDmu r\u016Fstov\u00E9mu faktoru (VEGF) a to cestou nav\u00E1z\u00E1n\u00ED jeho specifick\u00E9 isoformy VEGF165. Byla prezentov\u00E1na 1,5 let\u00E1 data o terapii vlhk\u00E9 formy VPMD pegaptanibem." . "Pegaptanib (Macugen) v l\u00E9\u010Db\u011B vlhk\u00E9 formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace, 1,5 let\u00E9 v\u00FDsledky"@cs . "macugen; safety of therapy; age related macular degeneration"@en . "Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year results"@en . . "Pegaptanib (Macugen) je v \u010Cesk\u00E9 republice dostupn\u00FD pro l\u00E9\u010Dbu neovaskul\u00E1rn\u00ED formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace od dubna 2007. Pegaptanib je de facto prvn\u00EDm z\u00E1stupcem l\u00E1tek p\u016Fsob\u00EDc\u00EDch proti vaskul\u00E1rn\u00EDmu r\u016Fstov\u00E9mu faktoru (VEGF) a to cestou nav\u00E1z\u00E1n\u00ED jeho specifick\u00E9 isoformy VEGF165. Byla prezentov\u00E1na 1,5 let\u00E1 data o terapii vlhk\u00E9 formy VPMD pegaptanibem."@cs . . "RIV/00216224:14110/09:00044516!RIV11-MSM-14110___" . "Pegaptanib (Macugen) v l\u00E9\u010Db\u011B vlhk\u00E9 formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace, 1,5 let\u00E9 v\u00FDsledky"@cs . "Pegaptanib (Macugen) v l\u00E9\u010Db\u011B vlhk\u00E9 formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace, 1,5 let\u00E9 v\u00FDsledky" . "RIV/00216224:14110/09:00044516" . . "Pegaptanib (Macugen) v l\u00E9\u010Db\u011B vlhk\u00E9 formy v\u011Bkem podm\u00EDn\u011Bn\u00E9 makul\u00E1rn\u00ED degenerace, 1,5 let\u00E9 v\u00FDsledky" . . "[67DB67F2BEAB]" . "332982" . . . . . "Kol\u00E1\u0159, Petr" . "Pegaptanib (Macugen) is available in the Czech Republic for the treatment of neovascular age-related macular degeneration since April 2007. Pegaptanib is a de facto representative of the first agents that interact with anti-vascular growth factor (VEGF) and through the connection to a specific isoform VEGF165. It was presented 1.5-year data on the treatment of wet AMD by pegaptanib."@en . "N" . "1"^^ . . . . . "1"^^ .